Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.X-Cell to test coronary stent system
Ethos I stents are coated with slow-release and moderate-release formulations of 17 beta-estradiol, an approved drug used in hormone replacement therapy and other indications. The trial is a
Ethos I stents are coated with slow-release and moderate-release formulations of 17 beta-estradiol, an approved drug used in hormone replacement therapy and other indications. The trial is a
Pfizer has gained exclusive worldwide development and commercialization rights to Incyte’s portfolio of CCR2 antagonist compounds, the most advanced of which is currently in phase IIa studies in
The randomized, placebo controlled multi-center clinical trial is designed to evaluate both objective parameters, such as improvement in urine flow and shrinkage of the prostate volume, as well
The FDA grants priority review to products it believes represent a therapeutic advance over existing medicines. By granting priority review status to Cubicin, the FDA has established a
According to the company, this financing will result in net proceeds to Solexa of approximately $61 million after deduction of offering expenses. Under the terms of the financing,
Tamiflu was already scheduled to be reviewed after it was approved for use in children in March 2004, but the evaluation took on greater significance following the deaths
These early-stage studies found Multiferon to be significantly more active against the virus than recombinant alpha interferon, recombinant beta interferon or ribavirin. The studies were conducted by Birmingham,
Adivar, sold as Serevent in Europe, is a major source of revenue for Glaxo, and shares in the company fell almost 5% after the news. GlaxoSmithKline criticized the
“Data such as these expand our understanding of the role Reyataz may play in anti-HIV regimens,” said Dr Jose Gatell, of the Hospital Clinic Provincial, Barcelona, Spain, and
This data, presented at the 9th European AIDS Conference, established that none of the 19 patients who met criteria for resistance testing and had resistance testing results available